Login
$AVBP
$11.56 +$0.00 (0.0%) After hours

$AVBP 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Continued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLC

26 Oct 2026 8-K: Regulation FD Disclosure; Other Events

ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026

19 Oct 2026 8-K: Regulation FD Disclosure

NEWTOWN SQUARE, PA, October 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic...

13 Oct 2026 8-K: Regulation FD Disclosure; Other Events

NEWTOWN SQUARE, PA, October 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutic...

06 Oct 2026 8-K: Regulation FD Disclosure; Other Events

ArriVent Announces Program Update from the Phase 3 FURVENT Trial of Firmonertinib in First-Line EGFR Exon 20 Insertion Mutant NSCLC

12 Aug 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026

22 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2026, ArriVent BioPharma, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 46,368,442 shares of common stock, par value $0.0001 per share,...

11 May 2026 8-K: Other Events

We have acted as counsel to ArriVent BioPharma, Inc., a Delaware corporation (the “Company”), with respect to certain matters in connection with the Automatic Shelf Registration Statement on Form S-3ASR (File No. 333-284661) (the “Regist...

11 May 2026 8-K: Results of Operations and Financial Condition

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026

17 Mar 2026 8-K: Regulation FD Disclosure; Other Events

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

05 Mar 2026 8-K: Results of Operations and Financial Condition

Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026

10 Nov 2025 8-K: Results of Operations and Financial Condition

Final Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC

09 Sep 2025 8-K: Regulation FD Disclosure; Other Events

Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer

11 Aug 2025 8-K: Results of Operations and Financial Condition

Positive interim Phase 1b update underscores firmonertinib’s potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025

21 Jul 2025 8-K: Other Events

ArriVent’s Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026

02 Jul 2025 8-K: Entry into a Material Definitive Agreement; Other Events

As representatives (the “Representatives”) of the several Underwriters

23 Jun 2025 8-K: Regulation FD Disclosure; Other Events

Arrivent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study

20 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 18, 2025, ArriVent BioPharma, Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 34,045,193 shares of common stock, par value $0.0001 per share,...

12 May 2025 8-K: Results of Operations and Financial Condition

Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations

28 Apr 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

NEWTOWN SQUARE, PA, April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics,...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support